IDH突变胶质瘤指南治疗后首年可靠认知变化:纵向多中心研究
本研究对127例初诊IDH突变胶质瘤患者手术前后进行神经心理学评估,并与匹配对照比较,采用可靠变化指数(RCI)校正练习效应。结果显示执行功能、学习/记忆和语言等域认知下降比例较高,年龄较大和放化疗可预测特定域及单项测试的认知下降。
要点
- IDH突变胶质瘤指南治疗后首年可出现多个认知域下降,执行功能、学习/记忆和语言较明显。
- 年龄较大和接受放化疗与特定认知域及单项测试的下降相关。
- 认知 deficits 是否持续或进展尚不明确,需长期随访。
核心结论
- 指南为基础的IDH突变胶质瘤治疗后首年多个认知域出现显著变化,年龄较大和放化疗增加认知下降风险,但 deficits 是否持续或进展未知。
研究设计与样本
- 纵向多中心研究,127例初诊IDH突变胶质瘤患者,手术前后进行神经心理学评估,并与匹配对照比较,计算可靠变化指数(RCI)。
主要发现
- 术前损伤比例为3%至24%,取决于具体测试。
- RCI域认知下降最大见于执行功能(24%)、学习/记忆(23%)和语言(21%)。
- 下降比例最大的单项测试为抑制/灵活性(32%)、命名速度(29%)、言语记忆(28%)、物体命名(28%)和言语流畅性(22%)。
- 回归模型显示年龄较大和放化疗预测特定域及单项测试的下降(P < 0.05)。
临床怎么用
- 对IDH突变胶质瘤患者按指南行多模态治疗时,应关注治疗前基线及治疗后首年认知功能,尤其执行功能、记忆和语言。
- 对年龄较大或接受放化疗者,可考虑认知监测与康复支持。
局限性
- 认知 deficits 是否持续或进展尚不明确,需更长随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Management of isocitrate dehydrogenase (IDH) mutated gliomas is multidisciplinary and current guidelines support early multimodal treatment. The effects of this treatment approach on cognition are less studied. We aimed to study changes in cognitive functioning the first year following treatment in these patients and explore predictors of cognitive deterioration. METHODS: Patients with a first-time diagnosis of IDH mutated glioma were neuropsychologically assessed before and one year after surgery. Results were compared to published norms, and impairment defined as z <-1.645. Matched controls were assessed at corresponding times, and reliable change indices (RCIs) were calculated to account for practice effects. Logistic regression models investigated predictors for cognitive declines. Tumor locations for declined versus non-declined patients were visualized using heatmaps. RESULTS: Of the 127 included patients, 104 underwent multi-modal treatment. Pre-operative impairments ranged from 3% to 24%, depending on the specific test. Cognitive declines according to RCI domains were largest in tests of executive functioning (24%), learning/memory (23%), and language (21%). Tests of inhibition/flexibility (32%), naming speed (29%), verbal memory (28%), object naming (28%), and verbal fluency (22%) showed the largest proportions of declines. Regression models revealed that older age and chemoradiotherapy predicted declines in specific domains as well as in individual tests (P < 0.05). CONCLUSIONS: Significant changes occurred in several cognitive domains after guideline-based treatment. Older age and chemoradiotherapy increased the risk of cognitive declines one year after surgery, but to which extent the deficits are persistent or progressing remains unknown.
引用
- Rydén I, Latini F, Alberius Munkhammar Å, et al. Reliable cognitive changes the first year following guideline-based treatment of isocitrate dehydrogenase mutated gliomas: A longitudinal multicenter study. Neuro Oncol. 2026. PMID: 41206933. doi:10.1093/neuonc/noaf263
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。